Skip to main content
Premium Trial:

Request an Annual Quote

Dennis Shields, Kevin Sayer

Premium
Dennis Shields was named the first member of Alfa Wassermann Proteomic Technologies’ scientific board last week. Shields is a professor of development and molecular biology, and anatomy and structural biology at the Albert Einstein College of Medicine. Shields received his PhD at the National Institute for Medical Research in London.
 

 
Eksigent said this week Kevin Sayer has joined its board. Sayer is a consultant to the drug and biotech industries with expertise in medical devices and finance, Eksigent said in a statement. Sayer has held positions at MiniMed/Medtronic MiniMed, Ernst & Young, and Specialty Labs.

The Scan

Tens of Millions Saved

The Associated Press writes that vaccines against COVID-19 saved an estimated 20 million lives in their first year.

Supersized Bacterium

NPR reports that researchers have found and characterized a bacterium that is visible to the naked eye.

Also Subvariants

Moderna says its bivalent SARS-CoV-2 vaccine leads to a strong immune response against Omicron subvariants, the Wall Street Journal reports.

Science Papers Present Gene-Edited Mouse Models of Liver Cancer, Hürthle Cell Carcinoma Analysis

In Science this week: a collection of mouse models of primary liver cancer, and more.